The OS benefit associated with standard treatment diminished in patients older than 80 with high comorbidity scores, but other age groups fared better.
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting.
Investigators concluded ixazomib “may offer a more convenient, active, and well-tolerated alternative to a parenterally administered PI in this setting.”
From 1990 to 2016, incident cases of multiple myeloma increased by 126% globally, while deaths increased 94%. The US had the most incident cases and deaths.
Most CLL patients treated with FCR will experience long-term remissions, but patients who relapse within 24 months have a dismal prognosis.
Findings from the MCC-Spain study suggest that in some cases, CLL could be prevented by modifying dietary habits.
For each 25 nmol/L increment of circulating vitamin D, colorectal cancer risk was 19% lower in women and 7% lower in men.
A 13% absolute increase in the radiographic response rate occurred in regorafenib-treated patients. Survival increases were not statistically significant.
AEs were more common in patients assigned to obinutuzumab compared with rituximab; however, baseline characteristics differed between treatment arms.
In the DAWN trial, however, investigators said, “some patients experienced prolonged remission durations and symptom relief with no new safety signals.”